COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04277637




Registration number
NCT04277637
Ethics application status
Date submitted
18/02/2020
Date registered
20/02/2020
Date last updated
21/09/2020

Titles & IDs
Public title
Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies
Scientific title
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Secondary ID [1] 0 0
BGB-11417-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mature B-Cell Malignancies 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BGB-11417

Experimental: BGB-11417 Monotherapy Dose Finding: Part 1 - Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined

Experimental: BGB-11417 Monotherapy Expansion Cohorts: Part 2 - Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile


Treatment: Drugs: BGB-11417
Film-coated tablets administered once daily at a dose as specified in the treatment arm

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
Timepoint [1] 0 0
Up to 30 days after the last dose of study drug, an average of 18 months
Primary outcome [2] 0 0
Number of Participants Experiencing Serious Adverse Events (SAEs)
Timepoint [2] 0 0
Up to 30 days after the last dose of study drug, an average of 18 months
Primary outcome [3] 0 0
Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of BGB-11417
Timepoint [3] 0 0
Up to 30 days after the last dose of study drug, an average of 18 months
Primary outcome [4] 0 0
Part 1, Part 3: Maximum Tolerated Dose (MTD)
Timepoint [4] 0 0
Day 1 to 21 days target dose of the study drug, an average of 18 months
Primary outcome [5] 0 0
Part 1, Part 3: Maximum RP2D of BGB-11417
Timepoint [5] 0 0
Day 1 to last dose of study drug, an average of 18 months
Primary outcome [6] 0 0
Part 1, Part 3: Number of participants experiencing tumor lysis syndrome (TLS) relevant events
Timepoint [6] 0 0
Up to 30 days after the last dose of study drug, an average of 18 months
Secondary outcome [1] 0 0
Maximum Observed Plasma Concentration (Cmax) of BGB-11417
Timepoint [1] 0 0
Predose up to 12 hours postdose
Secondary outcome [2] 0 0
Area Under the Concentration-Time Curve from Time 0 to the Last Quantifiable Concentration (AUC0-last) of BGB-11417
Timepoint [2] 0 0
Predose up to 12 hours postdose
Secondary outcome [3] 0 0
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-8) of BGB-11417
Timepoint [3] 0 0
Predose up to 12 hours postdose
Secondary outcome [4] 0 0
Time Taken for Half the Initial Dose Administered to Be Eliminated from The Body (T1/2) of BGB-11417
Timepoint [4] 0 0
Predose up to 12 hours postdose
Secondary outcome [5] 0 0
Time to Maximum Plasma Concentration (Tmax) of BGB-11417
Timepoint [5] 0 0
Predose up to 12 hours postdose
Secondary outcome [6] 0 0
Apparent Clearance (CL/F) of BGB-11417
Timepoint [6] 0 0
Predose up to 12 hours postdose
Secondary outcome [7] 0 0
Apparent volume of distribution (Vz/F) of BGB-11417
Timepoint [7] 0 0
Predose up to 12 hours postdose
Secondary outcome [8] 0 0
Steady State Area Under the Concentration-Time Curve of 0 - Last Day (AUCLast, ss) of BGB-11417
Timepoint [8] 0 0
Predose up to 12 hours postdose
Secondary outcome [9] 0 0
Steady State Maximum Observed Plasma Concentration (Cmax, ss) of BGB-11417
Timepoint [9] 0 0
Predose up to 12 hours postdose
Secondary outcome [10] 0 0
Steady State Trough Observed Plasma Concentration (Ctrough, SS) of BGB-11417
Timepoint [10] 0 0
Predose up to 12 hours postdose
Secondary outcome [11] 0 0
Steady State Time to Maximum Plasma Concentration (Tmax, ss) of BGB-11417
Timepoint [11] 0 0
Predose up to 12 hours postdose
Secondary outcome [12] 0 0
Part 2: AUC of BGB-11417 administered after a high fat/calorie meal (HF-Fed)
Timepoint [12] 0 0
Predose up to 12 hours postdose
Secondary outcome [13] 0 0
Part 2: Cmax of BGB-11417 administered after a high fat/calorie meal (HF-Fed)
Timepoint [13] 0 0
Predose up to 12 hours postdose
Secondary outcome [14] 0 0
Part 2, Part 4: Overall Response Rate (ORR) as Assessed by the Investigator - ORR is defined as the proportion of participants who had confirmed complete response Complete Response (CR) or Partial Response (PR)
Timepoint [14] 0 0
Up to 30 days after the last dose of study drug, an average of 18 months

Eligibility
Key inclusion criteria
Key

1. Confirmed diagnosis of one of the following:

NHL Cohorts:

a. MZL i. R/R extranodal, splenic, or nodal MZL defined as disease that relapsed
after, or was refractory to, at least two prior therapies ii. Active disease requiring
treatment b. FL i. R/R FL (Grade 1, 2 or 3a based on the WHO 2008 classification of
tumors of hematopoietic and lymphoid tissue) and defined as disease that relapsed
after, or was refractory to, at least 2 prior systemic therapies c. DLBCL i. R/R DLBCL
(including all subtypes of DLBCL) defined as disease that relapsed after, or was
refractory to, at least two prior systemic therapies and has either progressed
following or is not a candidate for autologous stem cell transplant (due to
comorbidities or non-responsiveness to salvage chemotherapy) d. Transformed indolent
B-cell NHL i. Any lymphoma otherwise eligible for Part 1 that has transformed into a
more aggressive lymphoma. Patients with transformation from CLL or SLL (Richter's
transformation) are not eligible for Part 1.

CLL/SLL Cohorts:

e. CLL/SLL diagnosis that meets the International Workshop on Chronic Lymphocytic
Leukemia (IWCLL) criteria i. Disease characterized as R/R disease defined as disease
that relapsed after, or was refractory to, at least 2 prior therapies ii. Requiring
treatment as defined by history

2. Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI),
defined as:

1. CLL: at least 1 lymph node > 1.5 cm in longest diameter and measurable in 2
perpendicular dimensions or clonal lymphocytes measured by flow cytometry

2. DLBCL, FL, MZL, SLL: at least 1 lymph node > 1.5 cm in longest diameter OR 1
extranodal lesion > 1.0 cm in the longest diameter, measurable in at least 2
perpendicular dimensions. For MZL, isolated splenomegaly is considered measurable
for this study

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

4. Adequate organ function

5. Adequate pancreatic function indicated by:

1. Serum amylase = 1.5 x upper limit of normal (ULN)

2. Serum lipase = 1.5 x ULN

Key
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known central nervous system involvement by lymphoma/leukemia

2. Known plasma cell neoplasm, prolymphocytic leukemia, history of or currently suspected
Richter's syndrome

3. Prior therapy = 2 months with or progression on a B-cell lymphoma-2 (Bcl-2) inhibitor

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Monash Medical Centre - Clayton
Recruitment hospital [2] 0 0
Concord REpatriation General Hospital - Concord
Recruitment hospital [3] 0 0
Peter McCallum Cancer Center - Melbourne
Recruitment hospital [4] 0 0
Linear Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
3168 - Clayton
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
3000 - Melbourne
Recruitment postcode(s) [4] 0 0
6009 - Nedlands

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the safety, tolerability; and to define the maximum
tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and
tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and
when given in combination with zanubrutinib.
Trial website
https://clinicaltrials.gov/show/NCT04277637
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
David Simpson
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BeiGene
Address 0 0
Country 0 0
Phone 0 0
1-877-828-5568
Fax 0 0
Email 0 0
clinicaltrials@beigene.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04277637